Isemid Den europeiske union - norsk - EMA (European Medicines Agency)

isemid

ceva santé animale - torasemide - high-ceiling diuretika, sulfonamider, vanlig - hunder - for behandling av kliniske tegn er relatert til hjertesvikt hos hund, blant annet lungeødem.

Feiba 50 E/ ml Norge - norsk - Statens legemiddelverk

feiba 50 e/ ml

baxalta innovations gmbh - faktor viii hemmer bypassaktivitet - pulver og væske til infusjonsvæske, oppløsning - 50 e/ ml

Gefitinib Mylan Den europeiske union - norsk - EMA (European Medicines Agency)

gefitinib mylan

mylan pharmaceuticals limited - gefitinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - gefitinib mylan er indisert som monoterapi for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke‑liten celle lunge kreft (nsclc) med aktiverende mutasjoner i egfr‑tk.

Plerixafor Accord Den europeiske union - norsk - EMA (European Medicines Agency)

plerixafor accord

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Iressa Den europeiske union - norsk - EMA (European Medicines Agency)

iressa

astrazeneca ab - gefitinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - iressa er indisert for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft med aktiverende mutasjoner av epidermal vekst-faktor-reseptor tyrosin kinase.

bicaVera 1,5% glukose 1,75 mmol Ca/l Norge - norsk - Statens legemiddelverk

bicavera 1,5% glukose 1,75 mmol ca/l

fresenius medical care deutschland gmbh - natriumklorid / natriumhydrogenkarbonat / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / glukosemonohydrat - peritonealdialysevæske - 11.57 g / 5.88 g / 0.5145 g / 0.2033 g / 33 g

bicaVera 2,3% glukose 1,75 mmol Ca/l Norge - norsk - Statens legemiddelverk

bicavera 2,3% glukose 1,75 mmol ca/l

fresenius medical care deutschland gmbh - natriumklorid / natriumhydrogenkarbonat / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / glukosemonohydrat - peritonealdialysevæske - 11.57 g / 5.88 g / 0.5145 g / 0.2033 g / 50 g

bicaVera 4,25% glukose 1,75 mmol Ca/l Norge - norsk - Statens legemiddelverk

bicavera 4,25% glukose 1,75 mmol ca/l

fresenius medical care deutschland gmbh - natriumklorid / natriumhydrogenkarbonat / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / glukosemonohydrat - peritonealdialysevæske - 11.57 g / 5.88 g / 0.5145 g / 0.2033 g / 93.5 g

bicaVera 1,5 % glukose, 1,25 mmol/l kalsium Norge - norsk - Statens legemiddelverk

bicavera 1,5 % glukose, 1,25 mmol/l kalsium

fresenius medical care deutschland gmbh - kalsiumkloriddihydrat / glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumhydrogenkarbonat - peritonealdialysevæske

bicaVera 2,3 % glukose, 1,25 mmol/l kalsium Norge - norsk - Statens legemiddelverk

bicavera 2,3 % glukose, 1,25 mmol/l kalsium

fresenius medical care deutschland gmbh - kalsiumkloriddihydrat / glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumhydrogenkarbonat - peritonealdialysevæske